These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21753772)

  • 1. L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.
    Hayashi K
    Hypertens Res; 2011 Aug; 34(8):910-2. PubMed ID: 21753772
    [No Abstract]   [Full Text] [Related]  

  • 2. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension in older adults: progress and limitations.
    Rich MW
    Am J Med; 2012 Oct; 125(10):949-50. PubMed ID: 22902034
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H; Kikuchi F; Ishida T
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central blood pressure under angiotensin and calcium channel blockade.
    Safar ME; Protogerou A; Blacher J
    Hypertension; 2009 Oct; 54(4):704-6. PubMed ID: 19667254
    [No Abstract]   [Full Text] [Related]  

  • 7. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M; Okubo S; Mizubayashi R; Isaka N; Machida H; Okamoto S; Hirota H; Takeuchi M; Kato T; Nakatani K; Mizuno O; Miyagawa K; Makino K; Okura T; Dohi Y; Ito M; Kimura G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.
    Matsui Y; Eguchi K; Ishikawa J; Shimada K; Kario K
    Am J Hypertens; 2011 Apr; 24(4):466-73. PubMed ID: 21164498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
    Tanifuji C; Suzuki Y; Geot WM; Horikoshi S; Takahashi H; Tomino Y
    Kidney Blood Press Res; 2009; 32(4):239-49. PubMed ID: 19752573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
    Saito I; Kushiro T; Zenimura N; Matsushita Y; Sagawa K; Hiramatsu K; Yamaguchi F
    J Nephrol; 2012; 25(5):699-708. PubMed ID: 22020401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
    Noda K; Hosoya M; Nakajima S; Ohashi J; Fukumoto Y; Shimokawa H
    Tohoku J Exp Med; 2012 Dec; 228(4):305-15. PubMed ID: 23124103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
    Iwai M; Chen R; Ide A; Iwanami J; Tomochika H; Tomono Y; Mogi M; Horiuchi M
    J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
    Uzui H; Morishita T; Nakano A; Amaya N; Fukuoka Y; Ishida K; Arakawa K; Lee JD; Tada H
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):304-9. PubMed ID: 24288395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.
    Hosoya M; Ohashi J; Sawada A; Takaki A; Shimokawa H
    Circ J; 2010 Apr; 74(4):798-806. PubMed ID: 20154404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus.
    Ushigome E; Matsumoto S; Oyabu C; Ushigome H; Yokota I; Hasegawa G; Nakamura N; Tanaka M; Yamazaki M; Fukui M
    J Am Soc Hypertens; 2017 Mar; 11(3):140-147. PubMed ID: 28089902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring.
    Parati G; Bilo G
    Hypertension; 2012 Jun; 59(6):1091-3. PubMed ID: 22547446
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
    Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
    J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.
    Nagasu H; Satoh M; Yorimitsu D; Tomita N; Sasaki T; Kashihara N
    Kidney Blood Press Res; 2011; 34(2):87-96. PubMed ID: 21273789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.